Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 3
2011 1
2012 1
2014 2
2018 2
2019 2
2020 1
2021 5
Text availability
Article attribute
Article type
Publication date

Search Results

16 results
Results by year
Filters applied: . Clear all
Page 1
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome.
Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecorps G, Mahaffey KW, Moryusef A, Pordy R, Quintero K, Roe MT, Sasiela WJ, Tamby JF, Tricoci P, White HD, Zeiher AM; ODYSSEY OUTCOMES Committees and Investigators. Schwartz GG, et al. N Engl J Med. 2018 Nov 29;379(22):2097-2107. doi: 10.1056/NEJMoa1801174. Epub 2018 Nov 7. N Engl J Med. 2018. PMID: 30403574 Free article. Clinical Trial.
Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial.
Ray KK, Colhoun HM, Szarek M, Baccara-Dinet M, Bhatt DL, Bittner VA, Budaj AJ, Diaz R, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Loizeau V, Lopes RD, Moryusef A, Murin J, Pordy R, Ristic AD, Roe MT, Tuñón J, White HD, Zeiher AM, Schwartz GG, Steg PG; ODYSSEY OUTCOMES Committees and Investigators. Ray KK, et al. Lancet Diabetes Endocrinol. 2019 Aug;7(8):618-628. doi: 10.1016/S2213-8587(19)30158-5. Epub 2019 Jul 1. Lancet Diabetes Endocrinol. 2019. PMID: 31272931 Free article. Clinical Trial.
Thrombin-receptor antagonist vorapaxar in acute coronary syndromes.
Tricoci P, Huang Z, Held C, Moliterno DJ, Armstrong PW, Van de Werf F, White HD, Aylward PE, Wallentin L, Chen E, Lokhnygina Y, Pei J, Leonardi S, Rorick TL, Kilian AM, Jennings LH, Ambrosio G, Bode C, Cequier A, Cornel JH, Diaz R, Erkan A, Huber K, Hudson MP, Jiang L, Jukema JW, Lewis BS, Lincoff AM, Montalescot G, Nicolau JC, Ogawa H, Pfisterer M, Prieto JC, Ruzyllo W, Sinnaeve PR, Storey RF, Valgimigli M, Whellan DJ, Widimsky P, Strony J, Harrington RA, Mahaffey KW; TRACER Investigators. Tricoci P, et al. N Engl J Med. 2012 Jan 5;366(1):20-33. doi: 10.1056/NEJMoa1109719. Epub 2011 Nov 13. N Engl J Med. 2012. PMID: 22077816 Free article. Clinical Trial.
Riboswitches as Drug Targets for Antibiotics.
Panchal V, Brenk R. Panchal V, et al. Antibiotics (Basel). 2021 Jan 5;10(1):45. doi: 10.3390/antibiotics10010045. Antibiotics (Basel). 2021. PMID: 33466288 Free PMC article. Review.
Fragment-Based Drug Discovery for RNA Targets.
Lundquist KP, Panchal V, Gotfredsen CH, Brenk R, Clausen MH. Lundquist KP, et al. Among authors: panchal v. ChemMedChem. 2021 Sep 6;16(17):2588-2603. doi: 10.1002/cmdc.202100324. Epub 2021 Aug 10. ChemMedChem. 2021. PMID: 34101375 Review.
Role of oxidative stress and autoimmunity in onset and progression of vitiligo.
Laddha NC, Dwivedi M, Mansuri MS, Singh M, Gani AR, Yeola AP, Panchal VN, Khan F, Dave DJ, Patel A, Madhavan SE, Gupta R, Marfatia Z, Marfatia YS, Begum R. Laddha NC, et al. Among authors: panchal vn. Exp Dermatol. 2014 May;23(5):352-3. doi: 10.1111/exd.12372. Exp Dermatol. 2014. PMID: 24628992
Atypical hemodynamic manifestations of cardiac tamponade.
Sharma N, Panchal V, Kalaria VG. Sharma N, et al. Among authors: panchal v. Catheter Cardiovasc Interv. 2004 Nov;63(3):339-45. doi: 10.1002/ccd.20187. Catheter Cardiovasc Interv. 2004. PMID: 15505862
16 results